The Prostate Cancer market dynamics are anticipated to change in the coming years owing to the rise in the number of companies taking interest in developing therapies.
“Prostate Cancer Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Prostate Cancer Market.
The Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Prostate Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about emerging therapies for the treatment of Prostate Cancer and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer Treatment.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Prostate Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Prostate Cancer Therapeutics Outlook
The available therapeutic treatment options in the Prostate Cancer Landscape aim to provide a cure to the patients suffering from this indication. However, there are several challenges that are yet to be tackled.
DelveInsight’s report covers around 200+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage products (Phase I), along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the Prostate Cancer Therapeutic Segment:
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Prostate Cancer Therapeutics Landscape
Globally, there are approx. 200+ key companies developing therapies for Prostate Cancer. Currently, Merck has its Prostate Cancer drug candidates in the most advanced stage of clinical development.
Some of the key Companies in the Prostate Cancer Therapeutics Market Include
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
Prostate Cancer Drugs Covered in the Report Include
-
Pembrolizumab: Merck & Co
-
Talazoparib: Pfizer
-
ODM-208: Orion
-
ZEN 3694: Zenith Epigenetics
-
EPI-7386: ESSA Pharma
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Prostate Cancer Current Treatment Patterns
4. Prostate Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Prostate Cancer Late Stage Products (Phase-III)
7. Prostate Cancer Mid-Stage Products (Phase-II)
8. Prostate Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prostate Cancer Discontinued Products
13. Prostate Cancer Product Profiles
14. Key Companies in the Prostate Cancer Market
15. Key Products in the Prostate Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Prostate Cancer Unmet Needs
18. Prostate Cancer Future Perspectives
19. Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Alpha-1 Antitrypsin Deficiency (A1ATD) Market
“Alpha-1 Antitrypsin Deficiency (A1ATD) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Alpha-1 Antitrypsin Deficiency (A1ATD) Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/